|Gross Div Yield||0.000%|
Biotechnology company specialising in developing healthcare products.
There are no upcoming dividends in this security at this time.
|BLIS Technologies Limited Update and Guidance||13 Mar 2014, 1:36pm||GENERAL|
|Ongoing Disclosure Notice - Alan James McKenzie||5 Mar 2014, 4:57pm||RELINT|
|Disclosure of Directors and Officers Relevant I...||29 Nov 2013, 8:30am||RELINT|
|SSH - Mingchun Qiu||26 Nov 2013, 2:12pm||SSH|
|Interim Half Year Report to 30 September 2013||22 Nov 2013, 11:31am||HALFYR|
The shares were listed in July 2001 following an equity placement in May 2001 to a group of NZ institutions at 73c per share, raising $6m. The company commenced business in August 2000 when it acquired from the University of Otago, rights to Salivaricin B, a substance which acts as a natural antibiotic to control streptococcal throat...(more)
This information was provided by BLIS Technologies Limited in their Half Year Report released on 22 November 2013: BLIS Technologies Ltd reports an operating loss of $764K on turnover of $721K for the six months to September 30. Turnover increased 24% from the $580K reported in the previous corresponding period. The operating loss ...(more)